ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1580

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): Design and Baseline Characteristics of Participants

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic

Authors

  • Farmer-Bailey, Heather, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
  • Cadnapaphornchai, Melissa A., Rocky Mountain Pediatric Kidney Center, Rocky Mountain Hospital for Children at Presbyterian St. Luke’s Medical Center, Denver, Colorado, United States
  • You, Zhiying, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
  • George, Diana, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
  • Wang, Wei, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
  • Jovanovich, Anna, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
  • Soranno, Danielle, Children's Hospital Colorado, Aurora, Colorado, United States
  • Gitomer, Berenice Y., University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
  • Chonchol, Michel, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
  • Nowak, Kristen L., University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States
Background

Complications of ADPKD begin in childhood. While the hallmark of the disease is the development and continued growth of multiple renal cysts that ultimately result in loss of kidney function, cardiovascular complications are the leading cause of death. Vascular dysfunction (endothelial dysfunction and large elastic artery stiffness) is evident from a very young age and appears to involve increased oxidative stress and inflammation. Treatment options to prevent cardiovascular disease in adults with ADPKD are limited; thus, childhood may represent a key therapeutic window.

Methods

Curcumin is a safe, naturally occurring polyphenol found in the Indian spice turmeric, with a unique ability to activate transcription of key antioxidants, suppress inflammation, and reduce proliferation. We are conducting an ongoing randomized, placebo-controlled, double-blind clinical trial to assess the effect of curcumin therapy (25 mg/kg/d) on vascular function (brachial artery flow-mediated dilation [FMDBA] and aortic pulse-wave velocity [aPWV]; co-primary outcomes) and kidney growth (change in height-adjusted total kidney volume [htTKV]) in children/young adults 6–25 yrs with ADPKD.

Results

The study is fully enrolled. Of the 68 screened participants, all 68 were randomized to receive either the curcumin or placebo. Participants ranged in age from 6-25 yrs, n=25 (37%) were children <18 yrs, and mean±S.D.estimated glomerular filtration rate was 117±16 ml/min/1.73m2. FMDBA was 9.3+0.5%, aPWV was 510+95 cm/sec, and median (IQR) htTKV was 333 (234, 475) ml/min. In the sub-group of young adults who received a supraphysiological infusion of ascorbic acid to inhibit vascular oxidative stress (n=24), FMDBA improved vs. isovolumetric saline (13.6±5.2% vs. 11.3±4.3%), indicating baseline vascular oxidative stress. Greater baseline aPWV was independently associated with larger baseline htTKV.

Conclusion

The trial will be completed in December of 2020. This study has the potential to establish a novel, safe, and facile therapy for the treatment of arterial dysfunction, and possibly renal cystic disease, in an understudied population of children and young adults with ADPKD.

Funding

  • NIDDK Support